Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNN-BC: Cisplatin, Nab-paclitaxel, Nivolumab and RT in MIBC
NCT05203913Phase 2Recruiting
- Sponsor
- Policlinico Gemelli
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in muscle-invasive bladder cancer (MIBC), sponsored by Policlinico Gemelli. Primary endpoint: Disease-free survival at 5 years. Started May 2023; status: recruiting.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT05203913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203913.